ArticleJournal of clinical medicine2021
TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between thyroid function and metabolic associated fatty liver disease: a systemic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- Association between thyroid function and nonalcoholic fatty liver disease: a dose-response meta-analysis.Frontiers in endocrinology · 2024Pooled it
- The role of hypothyroidism in cirrhosis pathogenesis: A retrospective cohort study and multi-omics integration analysis.PLoS genetics · 2025Article
- Thyroid function and hepatic fibrosis/cirrhosis: a two-sample Mendelian randomization study.Frontiers in genetics · 2025Article
- Impaired thyroid hormone sensitivity is associated with the degrees of fatty infiltration in metabolic dysfunction associated steatotic liver disease.Frontiers in endocrinology · 2025Article
- Pediatric MASLD: current understanding and practical approach.European journal of pediatrics · 2024Review
- Impaired sensitivity to thyroid hormone is associated with developing non-alcoholic fatty liver disease in euthyroid diabetic subjects.Frontiers in endocrinology · 2024Article
- Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease.International journal of molecular sciences · 2023Review
- Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.International journal of molecular sciences · 2023Review
- Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship?World journal of hepatology · 2023Review
- Article
- Association between hypothyroidism and liver fibrosis risk: a systematic review and meta-analysis.Clinical and experimental hepatology · 2022Article
- Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease.Metabolites · 2022Review
- Prevalence of hypothyroidism and effect of thyroid hormone replacement therapy in patients with non-alcoholic fatty liver disease: A population-based study.World journal of hepatology · 2022Article
- Targeting Thyroid Hormone/Thyroid Hormone Receptor Axis: An Attractive Therapy Strategy in Liver Diseases.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Thyroid hormones may be a risk factor for the development of non-alcoholic fatty liver disease (NAFLD) and its progression to liver fibrosis. The aim of this study is to investigate the relationship between thyroid stimulating hormone (TSH) levels, NAFLD, and liver fibrosis in the general population. A descriptive cross-sectional study was performed in subjects aged 18-75 years randomly selected from primary care centers between 2012 and 2016. Each subject underwent clinical evaluation, physical examination, blood tests and transient elastography. Descriptive and multivariate logistic regression analyses were used to identify factors associated with NAFLD and fibrosis. We included 2452 subjects (54 ± 12 years; 61% female). Subjects with TSH ≥ 2.5 μIU/mL were significantly associated with obesity, atherogenic dyslipidemia, metabolic syndrome (MetS), hypertransaminasemia and altered cholesterol and triglycerides. The prevalence of NAFLD and liver fibrosis was significantly higher in subjects with TSH ≥ 2.5 (μIU/mL). We found a 1.5 times increased risk of NAFLD, 1.8 and 2.3 times increased risk of liver fibrosis for cut-off points of ≥8.0 kPa and ≥9.2 kPa, respectively, in subjects with TSH ≥ 2.5 μIU/mL compared with TSH < 2.5 μIU/mL (control group), independent of the presence of MetS. These findings remained significant when stratifying TSH, with values ≥ 10 μIU/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.